Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?

by Zacks Equity Research

Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $76.84, moving -0.21% from the previous trading session.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.

Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration

by Zacks Equity Research

Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.

Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion

by Zacks Equity Research

Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $77.69, marking a +1.49% move from the previous day.

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $76.55, marking a +0.1% move from the previous day.

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

by Zacks Equity Research

Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQL

Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation

by Zacks Equity Research

The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.

Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout

by Zacks Equity Research

Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.

Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies

by Zacks Equity Research

Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.

Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $72.62, marking a -0.55% move from the previous day.

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $73.02, marking a +0.21% move from the previous day.

MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer

by Zacks Equity Research

MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.

Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Bristol Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $75.98, moving -0.26% from the previous trading session.

Roche (RHHBY) Gets EU Nod for Lunsumio, Tecentriq Label Expansion

by Zacks Equity Research

Roche (RHHBY) obtains EU approval for Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) and label expansion of Tecentriq.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

Bristol Myers Squibb (BMY) Stock Moves -0.54%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $76.18 in the latest trading session, marking a -0.54% move from the prior day.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Why Is Amicus Therapeutics (FOLD) Up 25.1% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.

BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer

by Zacks Equity Research

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.